CY1118518T1 - Αναστολεις της κινασης p38 μαp - Google Patents

Αναστολεις της κινασης p38 μαp

Info

Publication number
CY1118518T1
CY1118518T1 CY20171100002T CY171100002T CY1118518T1 CY 1118518 T1 CY1118518 T1 CY 1118518T1 CY 20171100002 T CY20171100002 T CY 20171100002T CY 171100002 T CY171100002 T CY 171100002T CY 1118518 T1 CY1118518 T1 CY 1118518T1
Authority
CY
Cyprus
Prior art keywords
optionally substituted
hydrogen
group
radical
inhibitors
Prior art date
Application number
CY20171100002T
Other languages
Greek (el)
English (en)
Inventor
David Charles Festus Moffat
Stéphane Pintat
Stephen Davies
Original Assignee
Chroma Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Chroma Therapeutics Limited filed Critical Chroma Therapeutics Limited
Publication of CY1118518T1 publication Critical patent/CY1118518T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100002T 2006-05-04 2017-01-02 Αναστολεις της κινασης p38 μαp CY1118518T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1118518T1 true CY1118518T1 (el) 2017-07-12

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100002T CY1118518T1 (el) 2006-05-04 2017-01-02 Αναστολεις της κινασης p38 μαp

Country Status (15)

Country Link
US (1) US8044211B2 (cg-RX-API-DMAC7.html)
EP (1) EP2013175B9 (cg-RX-API-DMAC7.html)
JP (1) JP5340918B2 (cg-RX-API-DMAC7.html)
KR (1) KR101429780B1 (cg-RX-API-DMAC7.html)
CN (1) CN102942520B (cg-RX-API-DMAC7.html)
AU (1) AU2007246869B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711310B8 (cg-RX-API-DMAC7.html)
CA (1) CA2650970C (cg-RX-API-DMAC7.html)
CY (1) CY1118518T1 (cg-RX-API-DMAC7.html)
DK (1) DK2013175T5 (cg-RX-API-DMAC7.html)
ES (1) ES2605727T3 (cg-RX-API-DMAC7.html)
HU (1) HUE033281T2 (cg-RX-API-DMAC7.html)
NZ (1) NZ573348A (cg-RX-API-DMAC7.html)
PT (1) PT2013175T (cg-RX-API-DMAC7.html)
WO (1) WO2007129040A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA017198B1 (ru) * 2006-10-30 2012-10-30 Хрома Терапьютикс Лтд. Гидроксаматы в качестве ингибиторов гистон-деацетилазы
CN101842361B (zh) 2007-06-27 2013-06-05 阿斯利康(瑞典)有限公司 吡嗪酮衍生物及其在治疗肺病中的用途
JP2011503042A (ja) * 2007-11-07 2011-01-27 クロマ セラピューティクス リミテッド p38MAPキナーゼ阻害剤
EP2245012B1 (en) 2008-02-29 2013-07-03 Chroma Therapeutics Limited Inhibitors of p38 map kinase
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
BR112015008167B1 (pt) 2012-10-17 2020-11-17 Macrophage Pharma Limited composto, composição farmacêutica, métodos para a inibição da atividade de uma enzima quinase map p38, para o tratamento ou a prevenção de doença autoimune ou inflamatória em um indivíduo, e para o tratamento, a melhoria ou a redução da incidência de doença proliferativa de células em um indivíduo, uso de composto, e, ácido
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0308429A (pt) * 2002-03-14 2005-01-11 Bayer Healthcare Ag Aroilpiridinonas monocìclicas como agentes antiinflamatórios
PL1877098T3 (pl) * 2005-05-05 2013-09-30 Glaxosmithkline Ip Dev Ltd Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
EP2245012B1 (en) * 2008-02-29 2013-07-03 Chroma Therapeutics Limited Inhibitors of p38 map kinase

Also Published As

Publication number Publication date
CN102942520A (zh) 2013-02-27
CA2650970C (en) 2014-09-16
CA2650970A1 (en) 2007-11-15
BRPI0711310B1 (pt) 2020-12-15
BRPI0711310A2 (pt) 2011-12-06
ES2605727T9 (es) 2020-12-11
ES2605727T3 (es) 2017-03-16
KR101429780B1 (ko) 2014-08-18
EP2013175B1 (en) 2016-11-09
HUE033281T2 (en) 2017-11-28
AU2007246869A1 (en) 2007-11-15
KR20090014187A (ko) 2009-02-06
EP2013175B9 (en) 2020-11-11
NZ573348A (en) 2012-01-12
PT2013175T (pt) 2017-02-14
DK2013175T3 (en) 2017-02-20
AU2007246869B2 (en) 2012-10-18
US20090099185A1 (en) 2009-04-16
WO2007129040A1 (en) 2007-11-15
BRPI0711310B8 (pt) 2021-05-25
EP2013175A1 (en) 2009-01-14
JP2009535385A (ja) 2009-10-01
US8044211B2 (en) 2011-10-25
JP5340918B2 (ja) 2013-11-13
DK2013175T5 (da) 2020-12-21
CN102942520B (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
CY1118518T1 (el) Αναστολεις της κινασης p38 μαp
EA200900519A1 (ru) Ингибиторы hdac
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
EA200500875A1 (ru) Производные 3-аминопирролидина в качестве модуляторов рецепторов хемокинов
CY1111706T1 (el) Παραγωγα αρυλο- και ετεροαρυλο-πιπεριδινοκαρβοξυλικων αλατων, η παρασκευη τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
ATE491454T1 (de) Verwendung von pyrrolo-pyrazinderivaten zur behandlung der zystischen fibrose
DK1940789T3 (da) Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
DK0767793T3 (da) N-substituerede-(dihydroxyboryl)alkylderivater af purin, indol og pyrimidin, som er nyttige som inhibitorer af inflammatoriske cytokiner
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
EA201100146A1 (ru) Растения, имеющие улучшенные характеристики урожайности, и способ их получения
CY1112394T1 (el) Παραγωγη fgf18 σε προκαρυωτικους ξενιστες
CR9959A (es) Derivados de pirazol
ATE385234T1 (de) Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren
MX346746B (es) Compuestos de anillo indeno-fusionados.
MX2009004442A (es) Inhibidores de la proteina cinasa de serina-treonina ikk-beta.
EA200201071A1 (ru) Циклопентилзамещенные производные глутарамида в качестве ингибиторов нейтральной эндопептидазы
MA29416B1 (fr) Inhibiteurs d'age
PE20121152A1 (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
ATE546467T1 (de) Ortho-nitrosophenole als polymerisationshemmer
GB0903480D0 (en) Enzyme Inhibitors
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
ATE469896T1 (de) Aminosäuresalze von rosiglitazon
BR0008589A (pt) Composto de tipirano, processo para sua preparação e seu uso
EA202192893A1 (ru) Среда для культивирования эукариотических клеток